"Ritonavir" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
An HIV protease inhibitor that works by interfering with the reproductive cycle of HIV. It also inhibits CYTOCHROME P-450 CYP3A.
| Descriptor ID |
D019438
|
| MeSH Number(s) |
D02.886.675.653 D03.383.129.708.653
|
| Concept/Terms |
|
Below are MeSH descriptors whose meaning is more general than "Ritonavir".
Below are MeSH descriptors whose meaning is more specific than "Ritonavir".
This graph shows the total number of publications written about "Ritonavir" by people in this website by year, and whether "Ritonavir" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2000 | 0 | 1 | 1 |
| 2004 | 1 | 0 | 1 |
| 2005 | 4 | 1 | 5 |
| 2007 | 3 | 0 | 3 |
| 2008 | 2 | 0 | 2 |
| 2009 | 4 | 0 | 4 |
| 2010 | 2 | 0 | 2 |
| 2011 | 4 | 0 | 4 |
| 2013 | 2 | 0 | 2 |
| 2014 | 2 | 1 | 3 |
| 2016 | 0 | 1 | 1 |
| 2019 | 1 | 0 | 1 |
| 2020 | 1 | 1 | 2 |
| 2021 | 1 | 0 | 1 |
| 2022 | 0 | 1 | 1 |
| 2023 | 2 | 0 | 2 |
| 2024 | 3 | 1 | 4 |
To return to the timeline,
click here.
Below are the most recent publications written about "Ritonavir" by people in Profiles.
-
COVID-19 vaccination modified the effect of nirmatrelvir-ritonavir on post-acute mortality and rehospitalization: a retrospective cohort study. Emerg Microbes Infect. 2024 Dec; 13(1):2421397.
-
Nirmatrelvir-Ritonavir and Symptoms in Adults With Postacute Sequelae of SARS-CoV-2 Infection: The STOP-PASC Randomized Clinical Trial. JAMA Intern Med. 2024 Sep 01; 184(9):1024-1034.
-
Association of nirmatrelvir-ritonavir with post-acute sequelae and mortality in patients admitted to hospital with COVID-19: a retrospective cohort study. Lancet Infect Dis. 2024 Oct; 24(10):1130-1140.
-
Emerging data in COVID-19 create urgent challengers for health providers: Updates on COVID-19 vaccine and Paxlovid. J Natl Med Assoc. 2024 Apr; 116(2 Pt 1):174-179.
-
Factors associated with the acceptability of Lopinavir/Ritonavir formulations among children living with HIV/AIDS attending care and treatment clinics in Mbeya and Mwanza, Tanzania. PLoS One. 2024; 19(1):e0292424.
-
Evaluation of SARS-CoV-2 RNA Rebound After Nirmatrelvir/Ritonavir Treatment in Randomized, Double-Blind, Placebo-Controlled Trials - United States and International Sites, 2021-2022. MMWR Morb Mortal Wkly Rep. 2023 Dec 22; 72(51):1365-1370.
-
Safely Prescribing Opioids With Nirmatrelvir/Ritonavir - Case Report and Management Recommendations. J Pain Symptom Manage. 2024 01; 67(1):e99-e104.
-
Clinical Outcomes Following Treatment for COVID-19 With Nirmatrelvir/Ritonavir and Molnupiravir Among Patients Living in Nursing Homes. JAMA Netw Open. 2023 04 03; 6(4):e2310887.
-
Rebound of SARS-CoV-2 Infection after Nirmatrelvir-Ritonavir Treatment. N Engl J Med. 2022 09 15; 387(11):1045-1047.
-
New Perspectives on Antimicrobial Agents: Molnupiravir and Nirmatrelvir/Ritonavir for Treatment of COVID-19. Antimicrob Agents Chemother. 2022 08 16; 66(8):e0240421.